Advice

following an abbreviated submission:

formoterol fumarate dihydrate / glycopyrronium / budesonide (Trixeo® Aerosphere) is accepted for restricted use within NHSScotland.

Indication under review: maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist.

SMC restriction: in patients with severe COPD (forced expiratory volume in one second [FEV1] less than 50% predicted normal).

Formoterol fumarate dihydrate / glycopyrronium / budesonide (Trixeo® Aerosphere) offers an additional treatment choice of long-acting beta2-agonist (LABA), long-acting muscarinic antagonist (LAMA) and inhaled corticosteroid (ICS) in a single inhaler.

Download detailed advice731KB (PDF)

Download

Medicine details

Medicine name:
formoterol fumarate dihydrate/glycopyrronium/budesonide (Trixeo Aerosphere)
SMC ID:
SMC2321
Indication:

Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long‑acting beta2‑agonist or combination of a long-acting beta2‑agonist and a long‑acting muscarinic antagonist.

Pharmaceutical company
AstraZeneca UK Ltd
BNF chapter
Respiratory system
Submission type
Abbreviated
Date advice published
08 February 2021